CLINICAL TRIALS PROFILE FOR HUMALOG
✉ Email this page to a colleague
All Clinical Trials for HUMALOG
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00046501 ↗ | Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents | Completed | Sanofi | Phase 3 | 2002-11-01 | The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro) |
| NCT00071448 ↗ | Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population | Completed | Novo Nordisk A/S | Phase 3 | 2002-06-01 | This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients. |
| NCT00097071 ↗ | Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents | Completed | Novo Nordisk A/S | Phase 3 | 2004-10-01 | This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes. |
| NCT00115570 ↗ | Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents | Completed | Sanofi | Phase 3 | 2005-04-01 | The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus. |
| NCT00191282 ↗ | Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 4 | 2002-10-01 | The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event (primary outcome defined as CV death, nonfatal myocardial infarction [MI], nonfatal stroke, coronary revascularization, or hospitalized acute coronary syndrome). |
| NCT00191581 ↗ | Local Registration Trial in China Humalog Mix 50 | Completed | Eli Lilly and Company | Phase 3 | 2005-03-01 | The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion in patients treated twice daily with insulin lispro mix 50/50. |
| NCT00206401 ↗ | Lantus in the Treatment of Type 1 Diabetes Children | Completed | Baylor College of Medicine | Phase 4 | 2004-11-01 | In this study, we plan to examine the difference in effect on blood glucose control in patients who will be on either conventional insulin therapy (i.e. using NPH and Humalog twice daily, injected separately) or on intensive insulin management (IIM-several shots of short acting and Glargine insulin). Those on IIM will be mixing the insulin Glargine with the short-acting insulin analog prior to injecting. The Hemoglobin A1c (HbA1c) results will be used to monitor blood glucose control over a 6 month period. Twice during the course of the study, a continuous glucose monitoring system (CGMS-a device the size of a pager that records blood sugar readings every 5 minutes) will be used to record all the changes in the blood glucose levels occurring over a 72-hour period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HUMALOG
Condition Name
Clinical Trial Locations for HUMALOG
Trials by Country
Clinical Trial Progress for HUMALOG
Clinical Trial Phase
Clinical Trial Sponsors for HUMALOG
Sponsor Name
